Veno-Occlusive Disease of the Liver after High-Dose Cytoreductive Therapy with Busulfan and Melphalan for Autologous Blood Stem Cell Transplantation in Multiple Myeloma Patients

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 12, 2007, Pages 1448-1454

  Carreras, Enric ^a   Rosiñol, Laura ^a   Terol, Maria José ^b   Alegre, Adrián ^c   de Arriba, Felipe ^d   García Laraña, José ^e   Bello, José Luis ^f   García, Raimundo ^g   León, Angel ^h   Martínez, Rafael ⁱ   Peñarrubia, M Jesús ^j   Poderós, Concha ^k   Ribas, Paz ^l   Ribera, Josep Maria ^m   San Miguel, Jesús ^m   Bladé, Joan ^a   Lahuerta, Juan José ⁿ  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL MORALES MESEGUER   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g GENERAL HOSPITAL   (Spain)

^h Manresa General Hospital   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^k HOSPITAL XERAL CÍES   (Spain)

^l Hospital Universitario ^*

^m HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

more..

Author keywords

Hepatoxicity; High dose therapy; Multiple myeloma; Veno occlusive disease

Indexed keywords

ALTEPLASE; ANTITHROMBIN III; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; DEFIBROTIDE; DIURETIC AGENT; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PREDNISONE; URSODEOXYCHOLIC ACID; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; INCIDENCE; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; STEM CELL MOBILIZATION; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; BUSULFAN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SPAIN; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 36048953435     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.08.002     Document Type: Article

References (54)

1. Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 64 (2000) 281-291
2. McDonald G.B., Hinds M.S., Fisher L.D., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118 (1993) 255-267
3. Carreras E., Bertz H., Arcese W., et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 92 (1998) 3599-3604
4. Bladé J., Rosiñol L., Sureda A., et al., Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA). High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106 (2005) 3755-3759
5. Lahuerta J.J., Martínez-López J., Grande C., et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. Br J Haematol 109 (2000) 138-147
6. Alegre A., Lamana M., Arranz R., et al. Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. Br J Haematol 91 (1995) 380-386
7. Tribalto M., Amadori S., Cudillo L., et al. Autologous peripheral blood stem cell transplantation as first-line treatment of multiple myeloma: an Italian Multicenter Study. Haematologica 85 (2000) 52-58
8. Jones R.J., Lee K.S., Beschorner W.E., et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 44 (1987) 778-783
9. Toh H.C., McAfee S.L., Sackstein R., et al. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 24 (1999) 891-895
10. Lee J.L., Gooley T., Bensinger W., et al. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 5 (1999) 306-315
11. Bornhauser M., Storer B., Slattery J.T., et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 102 (2003) 820-826
12. Srivastava A., Poonkuzhali B., Shaji R.V., et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 104 (2004) 1574-1577
13. Nieto Y., and Vaughan W.P. Pharmacokinetics of high-dose chemotherapy. Bone Marrow Transplant 33 (2004) 259-269
14. Grochow L.B. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 20 Suppl 4 (1993) 18-25
15. Slattery J.T., Sanders J.E., Buckner C.D., et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16 (1995) 31-42 Erratum in: Bone Marrow Transplant 1996;18(4):829
16. Dix S.P., Wingard J.R., Mullins R.E., et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 17 (1996) 225-230
17. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89 (1997) 3055-3060
18. Slattery J.T., and Risler L.J. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 20 (1998) 543-549
19. Clapes A., Sureda A., Sierra J., et al. Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage. Eur J Haematol 77 (2006) 1-6
20. Schuler U., Schroer S., Kuhnle A., et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?. Bone Marrow Transplant 14 (1994) 759-765
21. DeLeve L.D., and Kaplowitz N. Importance and regulation of hepatic glutathione. Semin Liver Dis 10 (1990) 251-266
22. Wu G., Fang Y.Z., Yang S., et al. Glutathione metabolism and its implications for health. J Nutr 134 (2004) 489-492
23. DeLeve L.D., and Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology 60 (2000) 143-154
24. McDonald G.B., Slattery J.T., Bouvier M.E., et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 101 (2003) 2043-2048
25. Ferrara F., Palmieri S., Annunziata M., et al. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation. Bone Marrow Transplant 34 (2004) 573-576
26. Samuels B.L., and Bitran J.D. High-dose intravenous melphalan: a review. J Clin Oncol 13 (1995) 1786-1799
27. Ayash L.J., Elias A., Schwartz G., et al. Double-dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol 14 (1996) 2984-2992
28. Singhal S., Powles R., Treleaven J., et al. Melphalan alone prior to allogeneic bone marrow transplantation from HLA- identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women. Bone Marrow Transplant 18 (1996) 1049-1055
29. Viens P., Maraninchi D., Legros M., et al. High-dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France. Bone Marrow Transplant 5 (1990) 227-233
30. 2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity. Br J Haematol 95 (1996) 527-530
31. Harousseau J.L., Milpied N., Laporte J.P., et al. Double-intensive therapy in high-risk multiple myeloma. Blood 79 (1992) 2827-2833
32. Moreau P., Hullin C., Garban F., et al., Intergroupe Francophone du Myelome. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood 107 (2006) 397-403
33. Corradini P., Tarella C., Zallio F., et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20 (2006) 1533-1538
34. Stewart D.A., Bahlis N., Valentine K., et al. Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 107 (2006) 4623-4627
35. Caballero M.D., Rubio V., Rifon J., et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 20 (1997) 451-458
36. Laskowitz D.T., Elion G.B., Dewhirst M.W., et al. Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion. Int J Hyperthermia 8 (1992) 111-120
37. Zhang J., Ye Z., and Lou Y. Metabolism of melphalan by rat liver microsomal glutathione S-transferase. Chem Biol Interact 152 (2005) 101-106
38. Lahuerta J.J., Grande C., Bladé J., et al., Spanish Multiple Myeloma Group. Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma. Leuk Lymphoma 43 (2002) 67-74
39. Loiseau H.A., Hartmann O., Valteau D., et al. High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 8 (1991) 465-472
40. Phillips G.L., Shepherd J.D., Barnett M.J., et al. Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy. J Clin Oncol 9 (1991) 1880-1888
41. Ren S., and Slatterly J.T. Inhibition of carboxyethylphosphoramide mustard formation from 4-hydroxycyclophosphamide by carmustine. AAPS PharmSci 1 (1999) E14
42. Jopperi-Davis K.S., Park M.S., Rogers L.K., et al. Compartmental inhibition of hepatic glutathione reductase activities by 1,3-bis(2-chloroethyl)-N-nitrosourea (BCNU) in Sprague-Dawley and Fischer-344 rats. Toxicol Lett 147 (2004) 219-228
43. Teicher B.A., Crawford J.M., Holden S.A., et al. Glutathione monoethyl ester can selectively protect liver from high-dose BCNU or cyclophosphamide. Cancer 62 (1988) 1275-1281
44. Ria R., Falzetti F., Ballanti S., et al. Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma. Hematol J 5 (2004) 118-122
45. Horvath N., Hahn U., Joshua D., et al. Long-term follow up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: a multimodality approach. Intern Med J 34 (2004) 167-175
46. Fermand J.P., Katsahian S., Divine M., et al., Group Myelome-Autogreffe. High-dose therapy and autologous blood stem cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23 (2005) 9227-9233
47. Srivastava A., Bradstock K.F., Szer J., et al. Busulphan and melphalan prior to autologous bone marrow transplantation. Bone Marrow Transplant 12 (1993) 323-329
48. Cony-Makhoul P., Marit G., Boiron J.M., et al. Busulphan and melphalan prior to autologous transplantation for myeloid malignancies. Bone Marrow Transplant 16 (1995) 69-70
49. Meloni G., Capria S., Vignetti M., et al. Ten-year follow-up of a single-center prospective trial of unmanipulated peripheral blood stem cell autograft and interferon-alpha in early-phase chronic myeloyd leukemia. Haematologica 86 (2001) 596-601
50. Drabko K., Zawitkowska-Klaczynska J., Wojcik B., et al. Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma. Pediatr Transplant 9 (2005) 618-621
51. Savarese D.M., Savy G., Vahdat L., et al. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 29 (2003) 501-513
52. Wang X., Kanel G.C., and DeLeve L.D. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat. Hepatology 31 (2000) 428-434
53. Chalandon Y., Roosnek E., Mermillod B., et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 10 (2004) 347-354
54. Kim S.E., Lee J.H., Choi S.J., et al. Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan. Haematologica 90 (2005) 285-286